Streetbeat News

Analyst Ratings

SEDG

SolarEdge Technologies Inc (NASDAQ:SEDG) reported a YoY decrease in earnings and weak top-line results, leading to a drop in its shares. The company's Q3 revenue decreased 27% YoY to $725.3 million, missing estimates of $768.38 million. SolarEdge reported a quarterly loss of 55 cents per share, compared to 91 cents in earnings last year. The company expects Q4 revenue to be between $300 million and $350 million. Multiple analysts downgraded the stock following the results.

Portfolio Pulse from Adam Eckert

November 02, 2023 | 1:30 pm

MELI

Wedbush analyst Scott Devitt has reiterated an Outperform rating on MercadoLibre (NASDAQ:MELI) and maintained a $1500 price target.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:29 pm

DRVN

Goldman Sachs analyst Kate McShane has maintained a Neutral rating on Driven Brands Hldgs (NASDAQ:DRVN) and lowered the price target from $21 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:27 pm

ABNB

Wedbush analyst Scott Devitt has maintained a Neutral rating on Airbnb (NASDAQ:ABNB) and lowered the price target from $145 to $135.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:27 pm

HARP

Harpoon Therapeutics, Inc. (NASDAQ:HARP) has announced that the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The event will take place from December 9-12, 2023, in San Diego.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:26 pm

EDIT

Editas Medicine, Inc. (NASDAQ:EDIT) will present clinical data from the RUBY and EdiTHAL trials of EDIT-301 at the ASH 2023 Annual Meeting and in a company-sponsored webinar. The data includes safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia. The company believes that EDIT-301 has the potential to be a clinically differentiated, one-time, durable medicine that can provide life-changing clinical benefits to patients.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:25 pm

CCU

Goldman Sachs has maintained a Neutral rating on United Breweries Co (NYSE:CCU) and lowered the price target from $14.8 to $12.9.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:24 pm

W

Wedbush analyst Seth Basham maintains an Outperform rating on Wayfair (NYSE:W) but has lowered the price target from $80 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:24 pm

AFMD

Affimed N.V. (NASDAQ:AFMD) announced the presentation of Phase 1/2 data from AFM13 in combination with allogeneic NK cells at the 2023 ASH Annual Meeting. The treatment showed a 94.4% objective response rate and a 72.2% complete response rate in 36 patients with CD30-positive lymphoma. The company also announced two upcoming presentations on its lead innate cell engager (ICE®) AFM13 at the ASH 2023 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:24 pm

GMAB

Genmab A/S (NASDAQ:GMAB) announced that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, have been accepted for presentation and publication at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH). The presentations will include data from several trials evaluating the safety and efficacy of epcoritamab as a monotherapy or in combination for the treatment of patients with various lymphoma subtypes. Results from a phase 1/2 trial evaluating GEN3014, an investigational novel human CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma will also be presented.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:23 pm